Related Directory Categories
- Indapamide (1)
Sources
Help build the largest human-edited directory on the web.
Submit a site - Become an editor
Wikipedia. Licensed under the GNU Free Documentation License.
Are you an expert in this subject? Join the discussion and share your knowledge at Wikipedia.org.
Indapamide
From Wikipedia, the free encyclopedia
 |
|
|
Indapamide
|
|
| Systematic (IUPAC) name | |
| 4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)- 3-sulfamoyl-benzamide | |
| Identifiers | |
| CAS number | |
| ATC code | C03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C16H16ClN3O3S |
| Mol. mass | 365.835 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 71-79% |
| Metabolism | Hepatic |
| Half life | 14-18 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Indapamide is a non-thiazide sulphonamide diuretic drug marketed by Servier, generally used in the treatment of hypertension and edema caused by congestive heart failure. Indapamide is marketed as Natrilix SR (sustained release). Combination preparations with perindopril (an ACE inhibitor antihypertensive) are also available.
Contents |
Each sustained-release coated tablet contains 1.5 mg of 1-(4-chloro-3-sulfamyl-benzamido)-2-methylindoline (or indapamide hemihydrate).
Essential hypertension.
One tablet daily.
Indapamide is contraindicated in known hypersensitivity to sulfonamides, severe renal failure, hepatic encephalopathy or severe hepatic failure and hypokalemia (low blood potassium levels).
There is insufficient safety data to recommend indapamide use in pregnancy or breastfeeding.
Caution is advised in the combination of indapamide with lithium and nonantiarrhythmic drugs causing wave burst arrhythmia (astemizole, bepridil, IV erythromycin, halofantrine, pentamidine, sultopride, terfenadine, vincamine).
Monitoring of potassium and uric acid serum levels is recommended, especially in subjects with a predisposition or a sensitivity to hypokalemia and in patients with gout.
Commonly reported adverse events are hypokalemia (low potassium levels), fatigue, orthostatic hypotension (blood pressure decrease on standing up) and allergic manifestations.
Symptoms of overdosage would be those associated with a diuretic effect: electrolyte disturbances, hypotension, and muscular weakness. Treatment should be symptomatic, directed at correcting the electrolyte abnormalities.
|
|
|
|---|---|
| Sympatholytic agents (including alpha) | centrally acting/antiadrenergics (Clonidine, Guanfacine, Methyldopa, Moxonidine, Rescinnamine, Reserpine, Rilmenidine) • ganglion-blocking/nicotinic antagonist (Mecamylamine, Trimethaphan) • peripherally acting/antiadrenergics (Prazosin, Guanethidine, Indoramin, Doxazosin) |
| Vasodilators | Diazoxide • Hydralazine • Minoxidil • Nitroprusside • Phentolamine |
| Other antihypertensives | serotonin antagonist (Ketanserin) • endothelin receptor antagonist (Bosentan, Ambrisentan, Sitaxsentan) |
| Low ceiling diuretics | Thiazide (Bendroflumethiazide, Chlorothiazide, Hydrochlorothiazide) • Chlortalidone • Indapamide • Quinethazone • Mersalyl • Metolazone • Theobromine • Cicletanine |
| High ceiling diuretics | Loop diuretic (Bumetanide, Furosemide, Torasemide) |
| Potassium-sparing diuretics | ESC blockers (Amiloride, Triamterene) • aldosterone antagonists (Spironolactone, Eplerenone, Potassium canrenoate, Canrenone) |